<bill session="108" type="h" number="2356" updated="2023-01-15T16:18:33Z">
  <state datetime="2003-06-05">REFERRED</state>
  <status>
    <introduced datetime="2003-06-05"/>
  </status>
  <introduced datetime="2003-06-05"/>
  <titles>
    <title type="display">Prescription Drug Comparative Effectiveness Act of 2003</title>
    <title type="official" as="introduced">To require the National Institutes of Health to conduct research, and the Agency for Healthcare Research and Quality to conduct studies, on the comparative effectiveness and cost-effectiveness of prescription drugs that account for high levels of expenditures or use by individuals in federally funded health programs, and for other purposes.</title>
    <title type="short" as="introduced">Prescription Drug Comparative Effectiveness Act of 2003</title>
  </titles>
  <sponsor bioguide_id="A000357"/>
  <cosponsors>
    <cosponsor bioguide_id="B000403" joined="2003-06-05"/>
    <cosponsor bioguide_id="B000420" joined="2003-06-05"/>
    <cosponsor bioguide_id="B001228" joined="2003-06-05"/>
    <cosponsor bioguide_id="B000944" joined="2003-07-09"/>
    <cosponsor bioguide_id="B001149" joined="2003-06-05"/>
    <cosponsor bioguide_id="C000754" joined="2003-06-05"/>
    <cosponsor bioguide_id="D000114" joined="2003-06-05"/>
    <cosponsor bioguide_id="E000092" joined="2003-10-30"/>
    <cosponsor bioguide_id="E000172" joined="2003-06-05"/>
    <cosponsor bioguide_id="G000410" joined="2003-10-30"/>
    <cosponsor bioguide_id="G000536" joined="2003-06-05"/>
    <cosponsor bioguide_id="K000220" joined="2003-10-30"/>
    <cosponsor bioguide_id="S000672" joined="2003-06-05"/>
    <cosponsor bioguide_id="W000119" joined="2003-06-05"/>
    <cosponsor bioguide_id="W000215" joined="2003-06-05"/>
  </cosponsors>
  <actions>
    <action datetime="2003-06-05">
      <text>Introduced in House</text>
    </action>
    <action datetime="2003-06-05" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2003-06-11">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Clinical trials"/>
    <term name="Communication in medicine"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Cost effectiveness"/>
    <term name="Drugs"/>
    <term name="Economics and Public Finance"/>
    <term name="Electronic government information"/>
    <term name="Federal aid to research"/>
    <term name="Government Operations and Politics"/>
    <term name="Government paperwork"/>
    <term name="Government publicity"/>
    <term name="Health information systems"/>
    <term name="Internet"/>
    <term name="Medicaid"/>
    <term name="Medical research"/>
    <term name="Medicare"/>
    <term name="Pharmaceutical research"/>
    <term name="Quality of care"/>
    <term name="Science, Technology, Communications"/>
    <term name="Social Welfare"/>
    <term name="Standards"/>
    <term name="Web sites"/>
  </subjects>
  <amendments/>
  <summary date="2006-11-28T17:35:40Z" status="Introduced in House">Prescription Drug Comparative Effectiveness Act of 2003 - Directs the Director of the National Institutes of Health, in coordination with the Director of the Agency for Healthcare Research and Quality, to conduct research to develop valid scientific evidence regarding the comparative effectiveness, cost-effectiveness, and (where appropriate) comparative safety relative to other drugs and treatments for the same disease or condition, of prescription drugs that account for high levels of expenditures or use by individuals in Federally funded health programs, including Medicare and Medicaid.Directs the Director of the Agency for Healthcare Research and Quality to: (1) analyze such evidence; and (2) develop standards for the design and conduct of cost-effectiveness studies under this Act.Establishes reporting requirements.</summary>
</bill>
